Insulet (PODD) 10-K Summary — Year Ended Dec 31, 2023
Insulet Corporation develops and sells tubeless insulin delivery systems for people with diabetes. In the most recent annual period, the company reported higher revenue compared to the prior year, along with positive operating income and net income.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
Insulet Corporation develops and sells tubeless insulin delivery systems for people with diabetes. In the most recent annual period, the company reported higher revenue compared to the prior year, along with positive operating income and net income.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$1.7B
Revenue reported for the fiscal year.
Operating income
$220.1M
Income from operations reported for the year.
Net income
$206.3M
Net income reported for the year.
Operating cash flow
$145.7M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $1.1B | n/a |
| Dec 31, 2022 | $1.3B | +18.8% |
| Dec 31, 2023 | $1.7B | +30.0% |
Business overview
Insulet is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery system, the Omnipod platform. The platform includes versions such as Omnipod DASH, Omnipod 5, and the newly cleared Omnipod GO, all of which eliminate the need for multiple daily injections or traditional insulin pumps with tubing.
Financial performance
Revenue increased from the prior year, and the company reported positive operating income and net income. Operating cash flow was also positive, reflecting the company's ability to generate cash from its operations.
Material risks
The filing references risk factors but the supplied context does not contain specific details on those risks. The company notes that its actual results could differ materially from forward-looking statements due to uncertainties and assumptions.
Liquidity and capital
The company held cash and cash equivalents and had total debt outstanding, including convertible senior notes. It also entered into capped call options to reduce potential dilution from conversion of those notes.
What to watch
Market adoption of the newly cleared Omnipod GO product in the next filing period.